Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Volunteers to Evaluate the Relative Bioavailability of a New Oral Formulation of Meloxicam, Movalis Capsules 15 mg, Versus Movalis Tablets 15 mg, After Administration Under Fasting State

Trial Profile

An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Volunteers to Evaluate the Relative Bioavailability of a New Oral Formulation of Meloxicam, Movalis Capsules 15 mg, Versus Movalis Tablets 15 mg, After Administration Under Fasting State

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Meloxicam (Primary)
  • Indications Ankylosing spondylitis; Back pain; Gout; Juvenile rheumatoid arthritis; Neuropathic pain; Osteoarthritis; Periarthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 12 Nov 2018 Status changed from recruiting to completed.
    • 09 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 01 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top